Jones Financial Companies
SLXN

Jones Financial Companies’s Silexion Therapeutics SLXN Stock Holding History

Jones Financial Companies’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32 Hold
3
– – ﹤0.01% 4683
2025
Q4 		$50 Buy
+3
New +$90 ﹤0.01% 4341

Other funds holding SLXN

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Jones Financial Companies's SLXN Position: Q1 2026 in Review

Jones Financial Companies held its Silexion Therapeutics (SLXN) position steady in Q1 2026 at 3 shares worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #4683.

Jones Financial Companies first reported a position in SLXN in Q4 2025 and has held it in 2 quarters since. The position peaked at $50 in Q4 2025. 7 funds tracked by Wall St. Rank hold SLXN as of Q1 2026.

  • Jones Financial Companies held 3 shares of Silexion Therapeutics worth $32 as of Q1 2026.
  • Jones Financial Companies left its Silexion Therapeutics share count unchanged in Q1 2026.
  • Silexion Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4683 holding.
  • Jones Financial Companies first reported a position in Silexion Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Jones Financial Companies's Silexion Therapeutics position peaked at $50 in Q4 2025.
  • 7 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.